References
- SEER Cancer Statistics. Cancer stat facts: myeloma; 2020 [cited 2020 Feb 27]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html.
- Nijhof IS, van de Donk N, Zweegman S, et al. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19–37.
- Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–734.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. Version 4.2021 [Updated December 10,2020; Accessed January 14, 2021]. Available from: http://www.nccn.org
- Kumar SK, Callander NS, Alsina M, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16(1):11–20.
- Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7.
- Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228–1263.
- Janssen Biotech Inc. DARZALEX (Daratumumab) prescribing information; 2019 [cited 2021 Apr 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s024lbl.pdf
- Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
- ODAC briefing document. FDA. Published February 26, 2019. https://www.fda.gov/media/121669/download. Cited 2021 Jul 27.
- Chari A, Vogl DT, Gavriatopoulou M, et al., Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8): 727–738.
- Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(9):859–866.
- Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187–1199.
- Tai YT, Mayes PA, Acharya C, et al. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–3138.
- Lonial S, Lee HC, Badros A, et al., Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2): 207–221.
- GlaxoSmithKline. BLENREP (Belantamab Mafodotin-blmf) prescribing information [ updated 2020;cited 2021 Jan 14]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036
- European Medicines Agency. BLENREP 100 mg powder. Summary of product characteristics. 2020 [cited 2021 Apr 22]. Available from: https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf.
- European Medicines Agency. Blenrep (belantmab mafodotin); 2020 [cited 2021 Apr 21]. Available from: https://www.ema.europa.eu/en/documents/overview/blenrep-epar-medicine-overview_en.pdf
- Suvannasankha A, Kapetanakis V, Prawitz T, et al., editors. Assessing efficacy via indirect comparison of single-agent belantamab mafodotin (Belamaf; GSK2857916) in DREAMM-2 versus STORM or MAMMOTH studies in relapsed/refractory multiple myeloma (RRMM). Society of Hematologic Oncology (SOHO) Annual Meeting; 2020 2020 Sept 9–12; Virtual Format.
- Institute for Clinical and Economic Review (ICER). Treatment options for relapsed or refractory multiple myeloma: effectiveness, value, and value-based price benchmarks: final evidence report and meeting summary; 2016 [updated 2016 Jun 9; cited 2021 Feb 23]. Available from: http://icerorg.wpengine.com/wp-content/uploads/2020/10/MWCEPAC_MM_Final_Evidence_Report_061016V3.pdf
- Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011 (last updated Mar 2013).
- Félix J, Aragão F, Almeida JM, et al. Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer. 2013;13:122.
- Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016.
- InHealth. Physicians’ fee & coding guide 2019. Commercial fee range - fees on disc. 2019.
- GlaxoSmithKline. Resource use survey: treatment of relapsed/refractory multiple myeloma in patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody (data on file). 2019.
- Pelligra CG, Parikh K, Guo S, et al. Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed–refractory multiple myeloma in the United States. Clin Ther. 2017;39(10):1986–2005.e5.
- Centers for Medicare & Medicaid Services. Physician fee schedule look-up tool 2019 [2019 Oct 24; Acessed 2019 Oct 24]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx.
- Karyopharm Therapeutics Inc. XPOVIO™ (Selinexor) prescribing information: U.S. Food and Drug Administration; [ updated 2020; accessed 2021 Jan 14]. Available from: https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf.
- IBM. Micromedex® REDBOOK® 2019 [Accessed: Oct 2019]. Available from: https://www.ibm.com/products/micromedex-red-book.
- Proskorovsky I, Lewis P, Williams CD, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014;12:35.
- Delforge M, Rodriguez-Otero P, Hari P, et al. Health state utility valuation in patients with triple-class-exposed relapsed and refractory multiple myeloma treated with the BCMA-directed CAR T cell therapy, Idecabtagene Vicleucel (ide-cel, bb2121): results from the KarMMa Trial. 62nd ASH Annual Meeting and Exposition; 2020 Dec 5-8; Virtual Format.
- Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force–7. Value Health. 2012;15:843–850.
- Vemer P, Corro Ramos I, van Voorn GA, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349–361.
- Institute for Clinical and Economic Review (ICER). ICER 2020-2023 value assessment framework 2020 [updated 2020 Oct 23; cited 2021 Apr 22]. Available from: http://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf.
- Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2018;24:29–38.
- Jakubowiak AJ, Campioni M, Benedict A, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016;19(11):1061–1074.
- National Institute for Health and Care Excellence. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma: technology appraisal guidance [TA510]. 2018.
- Ailawadhi S, DerSarkissian M, Duh MS, et al. Cost offsets in the treatment journeys of patients with relapsed/refractory multiple myeloma. Clin Ther. 2019;41(3):477–493.e7.
- Durie B, Binder G, Pashos C, et al. Total cost comparison in relapsed/refractory multiple myeloma. J Med Econ. 2013;16(5):614–622.
- Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8:204–215.
- Brown RE, Stern S, Dhanasiri S, et al. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ. 2013;14(3):507–514.
- Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690.
- Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4):410–420.
- HCUPnet. Weighted national estimates from HCUP National Inpatient Sample (NIS), 2016, Agency for Healthcare Research and Quality (AHRQ), based on data collected by individual States and provided to AHRQ by the States. Statistics by Principal Diagnosis and Payer (insurance status). 2016 [Accessed 2020 Oct 7]. Available from: https://www.hcup-us.ahrq.gov/nisoverview.jsp